Unknown

Dataset Information

0

18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.


ABSTRACT: Background:Noninvasively predicting early response to therapy in recurrent pediatric brain tumors provides a challenge. 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-FDOPA) PET/MRI has not been previously studied as a tool to evaluate early response to antiangiogenic therapy in children. The purpose of this study was to evaluate the safety and feasibility of using 18F-FDOPA PET/MRI to assess response to bevacizumab in children with relapsed brain tumors. Materials and Methods:Six patients with recurrent gliomas (5 low-grade, 1 high-grade) planned to undergo treatment with bevacizumab were enrolled. 18F-FDOPA PET/MRI scans were obtained prior to and 4 weeks following the start of treatment, and these were compared with the clinical response determined at the 3-month MRI. The primary PET measure was metabolic tumor volume (MTV) at 10 to 15 min after 18F-FDOPA injection. For each tumor, the MTV was determined by manually defining initial tumor volumes of interest (VOI) and then applying a 1.5-fold threshold relative to the mean standardized uptake value (SUV) of a VOI in the frontal lobe contralateral to the tumor. Results:18F-FDOPA PET/MRI was well tolerated by all patients. All tumors were well visualized with 18F-FDOPA on the initial study, with peak tumor uptake occurring approximately 10 min after injection. Maximum and mean SUVs as well as tumor-to-brain ratios were not predictors of response at 3 months. Changes in MTVs after therapy ranged from 23% to 98% (n = 5). There is a trend towards the percent MTV change seen on the 4-week scan correlating with progression-free survival. Conclusion:18F-FDOPA PET/MRI was well tolerated in pediatric patients and merits further investigation as an early predictor of response to therapy.

SUBMITTER: Gauvain K 

PROVIDER: S-EPMC5909807 | biostudies-other | 2018 Mar

REPOSITORIES: biostudies-other

altmetric image

Publications

<sup>18</sup>F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.

Gauvain Karen K   Ponisio Maria Rosana MR   Barone Amy A   Grimaldi Michael M   Parent Ephraim E   Leeds Hayden H   Goyal Manu M   Rubin Joshua J   McConathy Jonathan J  

Neuro-oncology practice 20170525 1


<h4>Background</h4>Noninvasively predicting early response to therapy in recurrent pediatric brain tumors provides a challenge. 3,4-dihydroxy-6-[<sup>18</sup>F]fluoro-L-phenylalanine (<sup>18</sup>F-FDOPA) PET/MRI has not been previously studied as a tool to evaluate early response to antiangiogenic therapy in children. The purpose of this study was to evaluate the safety and feasibility of using <sup>18</sup>F-FDOPA PET/MRI to assess response to bevacizumab in children with relapsed brain tumor  ...[more]

Similar Datasets

| S-EPMC8346454 | biostudies-literature
| S-EPMC4008691 | biostudies-literature
| S-EPMC6118093 | biostudies-literature
| S-EPMC7103504 | biostudies-literature
| S-EPMC5819614 | biostudies-literature
| S-EPMC5984283 | biostudies-other
| S-EPMC5439668 | biostudies-other
| S-EPMC5924589 | biostudies-literature
| S-EPMC7596690 | biostudies-literature
| S-EPMC3534417 | biostudies-literature